It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Studying survivorship and causes of death in patients with advanced or metastatic cancer remains an important task. We characterize the causes of death among patients with metastatic cancer, across 13 cancer types and 25 non-cancer causes and predict the risk of death after diagnosis from the diagnosed cancer versus other causes (e.g., stroke, heart disease, etc.). Among 1,030,937 US (1992–2019) metastatic cancer survivors, 82.6% of patients (n = 688,529) died due to the diagnosed cancer, while 17.4% (n = 145,006) died of competing causes. Patients with lung, pancreas, esophagus, and stomach tumors are the most likely to die of their metastatic cancer, while those with prostate and breast cancer have the lowest likelihood. The median survival time among patients living with metastases is 10 months; our Fine and Gray competing risk model predicts 1 year survival with area under the receiver operating characteristic curve of 0.754 (95% CI [0.754, 0.754]). Leading non-cancer deaths are heart disease (32.4%), chronic obstructive and pulmonary disease (7.9%), cerebrovascular disease (6.1%), and infection (4.1%).
Studying survivorship and causes of death in patients with metastatic cancer remains an important task. Here, the authors characterise the causes of death in over a million patients with metastatic cancer, and predict the risk of death after diagnosis due to cancer-related or other causes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Hsu, Melinda L. 5 ; Zaorsky, Nicholas G. 6
1 Albert Einstein School of Medicine, Bronx, USA (GRID:grid.501448.c); University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine, Department of Radiation Oncology, Cleveland, USA (GRID:grid.473817.e) (ISNI:0000 0004 0418 9795)
2 Penn State College of Medicine, Department of Public Health Sciences, Hershey, USA (GRID:grid.458418.4)
3 Penn State Cancer Institute, Department of Radiation Oncology, Hershey, USA (GRID:grid.458418.4); University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine, Department of Radiation Oncology, Cleveland, USA (GRID:grid.473817.e) (ISNI:0000 0004 0418 9795)
4 Case Western Reserve University, Department of Population and Quantitative Health Sciences, School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847)
5 University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine, Division of Hematology and Oncology, Cleveland, USA (GRID:grid.473817.e) (ISNI:0000 0004 0418 9795)
6 University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine, Department of Radiation Oncology, Cleveland, USA (GRID:grid.473817.e) (ISNI:0000 0004 0418 9795)




